Self-Reported Allergic Adverse Events Following Inactivated SARS-CoV-2 Vaccine (TURKOVAC™) among General and High-Risk Population

• Published in: Vaccines (Basel) 2023-02, Vol.11 (2), p.437
• Main Authors: Kara, Ateş, Coskun, Aslihan, Temel, Fehminaz, Özelci, Pervin, Topal, Selmur, Ates, İhsan
• Format: Article
• Language: English
• Subjects: Adverse and side effects; Adverse events; Age groups; Allergens; Allergic reaction; Allergic reactions; Allergies; Allergy; Anaphylaxis; Coronaviruses; COVID-19; COVID-19 vaccines; Deactivation; Drug dosages; Drugs; Health care facilities; Health services; Hypersensitivity (immediate); Immunization; Medical treatment; mRNA vaccines; Pandemics; Questionnaires; Risk factors; Self report; Severe acute respiratory syndrome coronavirus 2; Statistics; Surveys; vaccine; Vaccines; Virions
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines11020437

TURKOVAC™ is a whole-virion inactivated COVID-19 vaccine which was developed and granted emergency use and conditional marketing authorization in December 2021 in Türkiye. The objective of this study is to assess the distribution and the severity of allergic adverse events following the administration of the vaccine as the primary or the booster dose in 15 provinces in Türkiye. In this cohort study, between February and May 2022, in the selected 15 provinces having an adequate number of health care personnel in the community health centers to conduct the study, 32,300 people having the first, the second, or the booster dose of the vaccine were invited to the survey. A total of 29,584 people voluntarily agreed to participate to the survey and were given a structured questionnaire after a minimum of 10 days following the vaccination. In our study, only 0.5% of the participants (142 persons) reported to experience any allergic reaction, and 12 of them (8.5%) reported to be given medical treatment in a health center. Male predominance (55.6%) was observed among participants reported to experience any allergic reaction. No hospitalization was recorded. Of the participants, 4.4% (1315 people) reported to have a history of allergy. The most reported allergens were drugs. Among the participants without a known history of allergy ( = 28,269), 0.4% of them (110 people) reported to experience an allergic reaction following the vaccination, and 5.4% of the allergic reactions (six people) were reported to be treated in a health center. The percentage of the participants given any medical treatment among the participants without a known history of allergy is 0.02%. No immediate or anaphylactic reaction was reported. Among the participants with a known history of allergy ( = 1315), 32 people (2.4% of them) reported to experience an allergic reaction following the vaccination, and 18.7% of the allergic reactions (six people) were reported to be prescribed a medical treatment. The percentage of the participants given any medical treatment among the participants with a known history of allergy is 0.4% A known history of allergy increased the risk of having an allergic experience by approximately six times following vaccination. As a whole-virion inactivated SARS-CoV-2 vaccine, the TURKOVAC™ vaccine, with a low allergic reaction-related adverse event profile, can be an alternative to other COVID-19 vaccines.